Low free and bioavailable testosterone levels may predict pathologicallyproven high-risk prostate cancer: a prospective, clinical trial
- 1 January 2017
- journal article
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 43 (3) , 289-296
Abstract
Objective: To determine the predictive value of free and bioavailable testosterone levels on the detection of high-grade prostate cancer proven by histopathological examination of transrectal prostate biopsy specimens. Material and methods: A total of 405 patients who underwent transrectal prostate biopsy due to high prostatic specific antigen (PSA) (>2.5 ng/mL) and/or abnormal findings at digital rectal examination were included in this study. Blood free and bioavailable testosterone levels were calculated by the formula recommended by International Society for the Study of the Aging Male (ISSAM). The patients were stratified according to the D'Amico classification based on PSA levels and histological outcomes of prostate biopsies as benign, low, intermediate and high-risk prostate cancer. Patients were also divided into five groups according to the percentage of cancerous cores. Results: Prostate cancer was detected in 160 of 405 (39.5%) patients. Total, free and bioavailable testosterone levels did not differ significantly between the patients with benign or malign histology. However, mean free (6.2 vs. 5.2 ng/dL, p=0.02) and bioavailable (151 vs. 125 ng/dL, p=0.001) testosterone levels were found to be significantly different in men with low-intermediate and high-risk prostate cancer. Moreover, a significant correlation was found between free, and bioavailable testosterone levels and percentage of cores with cancer (p=0.002 for free and p=0.016 for bioavailable testosaterone, respectively). Conclusion: This prospective clinical study demonstrates that reduced levels of calculated blood free and bioavailable testosterone levels are associated with an increased risk of high-grade prostate cancer. Based on these findings blood free and bioavailable testosterone levels may be be thought to be an adjunctive factor in the prediction of high-risk prostate cancer. Cite this article as: Bayar G, Şirin H, Aydın M, Özağarı A, Tanrıverdi O, Kadıhasanoğlu M, et al. Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial. Turk J Urol 2017; 43: 289-96Keywords
This publication has 35 references indexed in Scilit:
- Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancerUrologic Oncology: Seminars and Original Investigations, 2015
- The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing ControversyJournal of Urology, 2015
- Testosterone therapy and prostate cancer—safety concerns are well foundedNature Reviews Urology, 2015
- Use of Testosterone Replacement Therapy in the United States and Its Effect on Subsequent Prostate Cancer OutcomesUrology, 2013
- Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8–10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancerBJU International, 2012
- Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatmentBJU International, 2012
- Testosterone and Prostate Cancer: What are the Risks for Middle-Aged Men?Urologic Clinics of North America, 2011
- Pretreatment Serum Testosterone Level as a Predictive Factor of Pathological Stage in Localized Prostate Cancer Patients Treated with Radical ProstatectomyEuropean Urology, 2005
- Low Serum Testosterone and a Younger Age Predict for a Poor Outcome in Metastatic Prostate CancerAmerican Journal of Clinical Oncology, 1997
- Occult Prostate Cancer in Men With Low Serum Testosterone LevelsJAMA, 1996